238 related articles for article (PubMed ID: 31183339)
1. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Butterworth RF
Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
3. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
Kumar A; Davuluri G; Silva RNE; Engelen MPKJ; Ten Have GAM; Prayson R; Deutz NEP; Dasarathy S
Hepatology; 2017 Jun; 65(6):2045-2058. PubMed ID: 28195332
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
5. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Canbay A; Sowa JP
Drugs; 2019 Feb; 79(Suppl 1):39-44. PubMed ID: 30706422
[TBL] [Abstract][Full Text] [Related]
6. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
Butterworth RF
Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246
[TBL] [Abstract][Full Text] [Related]
7. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia: Ammonia metabolism and hepatic encephalopathy.
Jindal A; Jagdish RK
Clin Mol Hepatol; 2019 Sep; 25(3):270-279. PubMed ID: 31006226
[TBL] [Abstract][Full Text] [Related]
9. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
10. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
11. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis.
Davuluri G; Krokowski D; Guan BJ; Kumar A; Thapaliya S; Singh D; Hatzoglou M; Dasarathy S
J Hepatol; 2016 Nov; 65(5):929-937. PubMed ID: 27318325
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
13. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO
Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219
[TBL] [Abstract][Full Text] [Related]
14. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Butterworth RF; Kircheis G; Hilger N; McPhail MJW
J Clin Exp Hepatol; 2018 Sep; 8(3):301-313. PubMed ID: 30302048
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels.
Gebhardt R; Beckers G; Gaunitz F; Haupt W; Jonitza D; Klein S; Scheja L
J Pharmacol Exp Ther; 1997 Oct; 283(1):1-6. PubMed ID: 9336301
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
19. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
[TBL] [Abstract][Full Text] [Related]
20. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
